dr. mcgregor on new combinations with immunotherapy in rcc
Published 6 years ago • 116 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
1:14
dr. mcgregor on the combination of atezolizumab and bevacizumab in rcc
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
1:47
dr. mcgregor on choosing a combination therapy regimen in advanced rcc
-
1:35
dr. grigg on immunotherapy/tki combinations in rcc
-
3:01
potential immunotherapy combinations in rcc
-
1:23
dr. mcgregor on unmet needs in advanced rcc
-
1:02
dr. gupta discusses combination immunotherapy in rcc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
1:03
dr. mcgregor on the evolving treatment landscape of rcc
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
1:00
dr. zibelman on combinations of immunotherapy for rcc
-
1:19
dr. mcgregor compares recent data with combinations in rcc
-
0:53
immunotherapy combination strategies in rcc